Scientific Rigour at the Core of Every Early-Phase Study
Early-phase clinical studies are not just safety exercises. They are the first opportunity to generate human pharmacokinetic, pharmacodynamic, and translational data, the data that will shape every subsequent development decision.
Accelsiors brings deep expertise in PK/PD analysis, pharmacometrics, modelling and simulation, and biomarker strategy. This expertise is not a bolt-on service. It is embedded into the study design, execution, and interpretation from the outset.
Our teams ensure that:
- PK sampling strategies are designed to support robust parameter estimation and inform dose selection for subsequent studies
- PD biomarker endpoints are selected, validated, and operationally feasible within the study setting
- Modelling and simulation are used to support dose escalation decisions, predict exposure-response relationships, and inform go/no-go assessments
- Translational hypotheses from preclinical development are tested with clinical data in a structured, interpretable framework
In pediatric programmes, these capabilities take on additional importance. Dose modelling in young populations, particularly using population PK, physiologically-based pharmacokinetic (PBPK) modelling, and maturation-based scaling, is essential for establishing safe and pharmacologically rational starting doses. Biomarker strategies must be redesigned for pediatric feasibility, accounting for sample volume constraints, assay sensitivity in smaller samples, and the practical realities of specimen collection in young children. Pharmacometric bridging from adult to pediatric populations requires rigorous modelling that regulatory agencies increasingly expect to see as part of pediatric development submissions.
The goal is not just to collect data. It is to generate the pharmacological and translational evidence that enables confident progression or, when necessary, early and informed course correction.
